DL-亮氨酰-DL-亮氨酸 | 2883-36-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: DL-亮氨酰-DL-亮氨酸
• 英文名称: leucylleucine
• 英文别名: 2-[(2-azaniumyl-4-methylpentanoyl)amino]-4-methylpentanoate
• CAS: 2883-36-5
• 化学式: C₁₂H₂₄N₂O₃
• mdl: MFCD00026508
• 分子量: 244.334
• InChiKey: LCPYQJIKPJDLLB-UHFFFAOYSA-N

物化性质

• 沸点：
  432.7±30.0 °C(Predicted)
• 密度：
  1.051±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• WGK Germany：
  3
• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  DL-亮氨酰-DL-亮氨酸 在 sodium hydroxide 、 氨 作用下， 生成 glycyl=>leucyl=>leucine
  参考文献：
  名称：

  Abderhalden; Fleischmann, Fermentforschung, vol. 9, p. 527

  摘要：

  DOI：
• 作为产物：
  描述：

  DL-亮氨酸 在 sodium hydroxide 、 氨 、 水 作用下， 生成 DL-亮氨酰-DL-亮氨酸
  参考文献：
  名称：

  Fischer,E.; Koelker, Justus Liebigs Annalen der Chemie, 1907, vol. 354, p. 40,44, 46

  摘要：

  DOI：

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERGLYCEMIA AND METABOLIC SYNDROME
  申请人：Alapati Mohan Murali

  公开号：US20160272582A1

  公开（公告）日：2016-09-22

  The invention relates to the compounds and compositions of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.

  本发明涉及化合物和组合物的公式I、公式II、公式III、公式IV、公式V、公式VI或其药学上可接受的多晶形、溶剂化物、对映体、立体异构体和水合物。该药物组合物包括二甲双胍盐，并且可制备用于口服、颊黏膜、直肠、局部、经皮、经黏膜、静脉、肌肉注射、糖浆或注射的治疗或预防代谢综合征、糖尿病前期和糖尿病的方法。这些组合物可用于治疗糖尿病、肥胖症、脂质代谢紊乱、高甘油三酯血症、高血糖、高胰岛素血症和胰岛素抵抗。
• SUBSTRATE FOR ASSAYING BETA-GLUCAN AND/OR ENDOTOXIN AND ASSAY METHOD
  申请人：Kitagawa Takeshi

  公开号：US20100330700A1

  公开（公告）日：2010-12-30

  An object of the present invention is to provide a peptide derivative for determining β-glucan or endotoxin which allows high sensitivity measurement, and a method for determining β-glucan and/or endotoxin using the same. The present invention relates to (1) a peptide derivative represented by the following general formula [1]: X-A 1 -Gly-Arg-A 2 -E-D  [1], (2) a reagent for determining β-glucan and/or endotoxin comprising the above-described peptide derivative, (3) a method for determining β-glucan and/or endotoxin, characterized in that a sample containing β-glucan and/or endotoxin, an amebocyte lysate of a horseshoe crab and the above-described peptide derivative are reacted each other, then the resulting released compound represented by the following general formula [2]: H-A 2 -E-D  [2] is separated from unreacted substance and quantified, and the determination is made based on this value, and (4) a reagent kit for determining β-glucan and/or endotoxin, comprising an amebocyte lysate of a horseshoe crab and the above-described peptide derivative as constituents thereof.

  本发明的目的是提供一种用于测定β-葡聚糖或内毒素的肽衍生物，该肽衍生物允许高灵敏度测量，并提供使用该肽衍生物测定β-葡聚糖和/或内毒素的方法。本发明涉及(1)由以下通式[1]表示的肽衍生物：X-A1-Gly-Arg-A2-E-D[1]，(2)用上述肽衍生物的试剂用于测定β-葡聚糖和/或内毒素，(3)一种用于测定β-葡聚糖和/或内毒素的方法，其特征在于将含有β-葡聚糖和/或内毒素的样品、一种马蹄蟹的阿米巴溶解液和上述肽衍生物反应，然后分离出代表以下通式[2]的所释放的化合物：H-A2-E-D[2]，并对此值进行定量测定，然后进行测定，以及(4)用于测定β-葡聚糖和/或内毒素的试剂盒，其包括一种马蹄蟹的阿米巴溶解液和上述肽衍生物作为其组分。
• Novel 2-oxoimidazolidine derivative, a process for preparing same and a pharmaceutical composition containing the 2-oxoimidazolidine derivative
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：EP0052696A1

  公开（公告）日：1982-06-02

  A 2-oxoimidazolidine derivative of the formula: wherein R1 is lower alkyl or phenyl-lower alkyl and R2 is lower alkyl or phenyl, and a process for preparation thereof are disclosed. Said 2-oxoimidazolidine derivative (I) or a pharmaceutically acceptable salt thereof in form of a pharmaceutical composition exhibits useful hypotensive activity.

  本发明公开了一种式如下的 2-氧代咪唑烷衍生物： 其中 R1 为低级烷基或苯基-低级烷基，R2 为低级烷基或苯基，本发明公开了一种 2-氧代咪唑烷衍生物及其制备方法。所述 2-氧代咪唑烷衍生物 (I) 或其药学上可接受的盐以药物组合物的形式表现出有用的降血压活性。
• 2-Oxo-imidazolidine compounds, a process for preparing the same and a pharmaceutical composition
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：EP0095163A2

  公开（公告）日：1983-11-30

  Novel 2-oxo-imidazolidine derivative of the formula: wherein R1 is lower alkyl or phenyl-lower alkyl, R2 is lower alkyl, R3 is alkyl of one to 12 carbon atoms or phenyl-lower alkyl and R4 is hydrogen or lower alkyl, pharmaceutically acceptable salts thereof and processes for preparing the same are disclosed. In form of pharmaceutical compositions said compounds (I) and salts thereof exhibit hypotensive activity.

  式中的新型 2-氧代咪唑烷衍生物： 其中，R1 是低级烷基或苯基低级烷基，R2 是低级烷基，R3 是 1 至 12 个碳原子的烷基或苯基低级烷基，R4 是氢或低级烷基，公开了其药学上可接受的盐及其制备工艺。以药物组合物的形式，所述化合物 (I) 及其盐类具有降血压活性。
• Pharmaceutical compositions
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0145228A1

  公开（公告）日：1985-06-19

  Zinc (11) complexes in which at least one ligand is provided by a compound being: (1) 3-hydroxy-4-pyrone or a 3-hydroxy-4-pyrone in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic hydrocarbon group of 1 to 6 carbon atoms; or (2) a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionisable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group; are of value in medicine, particularly in the systemic treatment of zinc depletion. Mixtures of these zinc complexes with the metal-free compound(s) providing the ligands contained therein and with iron (III) complexes containing ligands of types (1) and (2) are also of value.

  锌(11)配合物，其中至少一种配体由以下化合物提供： (1) 3-羟基-4-吡喃酮或 3-羟基-4-吡喃酮，其中与环碳原子相连的一个或多个氢原子被 1 至 6 个碳原子的脂肪族烃基取代；或 (2) 3-羟基吡啶-2-酮或 3-羟基吡啶-4-酮，其中与氮原子相连的氢原子被脂族酰基、1 至 6 个碳原子的脂族烃基取代，或被选自脂族酰基、烷氧基、脂族胺、脂族酰胺、羧基的一个或一个以上取代基取代（可电离基团除外）的脂族烃基取代、脂肪族酰胺、羧基、脂肪族酯、卤素、羟基和砜基，可选地，其中一个或多个与环碳原子相连的氢原子被上述取代基之一、1 至 6 个碳原子的脂肪族烃基或被烷氧基、脂肪族酯、卤素或羟基取代的脂肪族烃基所取代；具有医药价值，特别是在系统治疗锌缺乏症方面。这些锌络合物与提供其中所含配体的无金属化合物的混合物，以及与含有(1)和(2)型配体的铁(III)络合物的混合物也很有价值。

表征谱图